| Literature DB >> 28219000 |
T Bake1, K T Hellgren1, S L Dickson1.
Abstract
Ghrelin, an orexigenic hormone released from the empty stomach, provides a gut-brain signal that promotes many appetitive behaviours, including anticipatory and goal-directed behaviours for palatable treats high in sugar and/or fat. In the present study, we aimed to determine whether ghrelin is able to influence and/or may even have a role in binge-like eating behaviour in rodents. Accordingly, we used a palatable scheduled feeding (PSF) paradigm in which ad lib. chow-fed rodents are trained to 'binge' on a high-fat diet (HFD) offered each day for a limited period of 2 hours. After 2 weeks of habituation to this paradigm, on the test day and immediately prior to the 2-hour PSF, rats were administered ghrelin or vehicle solution by the i.c.v. route. Remarkably and unexpectedly, during the palatable scheduled feed, when rats normally only binge on the HFD, those injected with i.c.v. ghrelin started to eat more chow and chow intake remained above baseline for the rest of the 24-hour day. We identify the ventral tegmental area (VTA) (a key brain area involved in food reward) as a substrate involved because these effects could be reproduced, in part, by intra-VTA delivery of ghrelin. Fasting, which increases endogenous ghrelin, immediately prior to a palatable schedule feed also increased chow intake during/after the schedule feed but, in contrast to ghrelin injection, did not reduce HFD intake. Chronic continuous central ghrelin infusion over several weeks enhanced binge-like behaviour in palatable schedule fed rats. Over a 4-week period, GHS-R1A-KO mice were able to adapt and maintain large meals of HFD in a manner similar to wild-type mice, suggesting that ghrelin signalling may not have a critical role in the acquisition or maintenance in this kind of feeding behaviour. In conclusion, ghrelin appears to act as a modulating factor for binge-like eating behaviour by shifting food preference towards a more nutritious choice (from HFD to chow), with these effects being somewhat divergent from fasting.Entities:
Keywords: GHS-R1A; binge eating; dietary preference; food choice; ghrelin; high-fat diet
Mesh:
Substances:
Year: 2017 PMID: 28219000 PMCID: PMC5434925 DOI: 10.1111/jne.12463
Source DB: PubMed Journal: J Neuroendocrinol ISSN: 0953-8194 Impact factor: 3.627
Figure 1Effects of acute i.c.v. ghrelin injection and a 16 hours fast on energy intake and food preference in rats exposed to a palatable schedule feeding (PSF)‐paradigm. For injection studies, artificial cerebrospinal fluid (aCSF) was administered as vehicle control solution and ghrelin was administered at two different doses (1 and 2 μg). (A) Cumulative energy intake from high‐fat diet (HDF) during a 2 hr‐palatable schedule feed (2 hr‐PSF). (B) Cumulative energy intake from chow during the 2 hr‐PSF. (C) Cumulative total energy intake (combined from HFD and chow) during the 2 hr‐PSF. (D) Percentage of HFD in relation to chow during the 2 hr‐PSF. (E) Cumulative energy intake from chow up to 24 hours post‐injection. (F) Cumulative total energy intake (combined from HFD and chow) up to 24 hours post‐injection. (G) Percentage of HFD in relation to chow in the 24 hours post‐injection period. Data are presented as the mean±SEM. *P<.05 vs vehicle, # P<.05 vs fasting by one‐way ANOVA (n=16 rats)
Figure 2Effects of acute intra‐VTA ghrelin and a 16 hours fast on energy intake and food preference in rats exposed to a palatable schedule feeding (PSF)‐paradigm. Artificial cerebrospinal fluid (aCSF) was administered as vehicle control solution and ghrelin was administered at two different doses (0.5 and 1 μg). (A) Cumulative energy intake from a high‐fat diet (HDF) during a 2‐hour palatable schedule feed (2 hr‐PSF). (B) Cumulative energy intake from chow during the 2 hr‐PSF. (C) Cumulative total energy intake (combined from HFD and chow) during the 2 hr‐PSF. (D) Percentage of HFD in relation to chow during the 2 hr‐PSF. (E) Cumulative energy intake from chow up to 24 hours post‐injection. (F) Cumulative total energy intake (combined from HFD and chow) up to 24 hours post‐injection. (G) Percentage of HFD in relation to chow in the 24 hours post‐injection period. Data are presented as the mean±SEM. *P<.05 vs vehicle, # P<.05 vs fasting by one‐way ANOVA (n=15 rats)
Figure 3Effects of chronic i.c.v. ghrelin delivery over 4 weeks in rats exposed to a palatable feeding schedule (PSF)‐paradigm. (A) Body weight development over pre‐surgery, chow feeding and scheduled feeding phases. (B) Body weight gain during 10 days of chow feeding. (C) Body weight gain over 18 days exposure to the PSF‐paradigm. (D) Total daily energy intake over pre‐surgery, chow feeding and palatable scheduled feeding phases. (E‐G) Energy intake during palatable scheduled feeding phase: (E) Energy intake from a high‐fat diet (HDF) during the 2‐hour palatable schedule feed (2 hr‐PSF); (F) Energy intake from chow during the 2 hr‐PSF; and (G) Energy intake from chow during the remaining 22 hours. Ghrelin (closed circles) vs vehicle (open circles). Data are presented as the mean±SEM. *P<.05; **P<.01; ***P<.001 by independent samples t‐test (n=8 rats per group)
Figure 4Palatable schedule feeding in ghrelin receptor knockout mice. Over 4 weeks, GHS‐R1A knockout (KO; closed circles) mice and their wild‐type (WT; open circles) littermates were either fed normal chow ad libitum (WT‐PSF and WT‐con; grey) or exposed to a palatable feeding schedule (PSF)‐paradigm (KO‐PSF and WT‐PSF; black). (A) Total daily energy intake. (B) Energy intake from a high‐fat diet (HDF) during the 2‐hour palatable scheduled feed (2 hr‐PSF). (C) Energy intake from chow during the 2 hr‐PSF. (D) Energy intake from chow during the remaining 22 hours. (E) Percentage of energy intake during the 2 hr‐PSF and during the remaining 22 hours. (F) Body weight gain. (G) Body fat mass as percentage of body weight gain after 4 weeks on the respective feeding paradigms. Data are presented as the mean±SEM. *P<.05; **P<.01; ***P<.001 by two‐way ANOVA with factors feeding paradigm (PSF‐paradigm vs con) or genotype (KO vs WT) (n=6‐7 mice per group)